TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11358831
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

  2000cited by this paper
• In search of the tumour-suppressor functions of BRCA1 and BRCA2

  2000cited by this paper
• BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

  2000cited by this paper
• Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer.

  2000cited by this paper
• Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.

  1999cited by this paper
• Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

  1999cited by this paper
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

  1999cited by this paper
• Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

  1999cited by this paper
• The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter

  1999cited by this paper
• Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

  1999cited by this paper
• Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features

  1999influential reference
• BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.

  1999cited by this paper
• Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours

  1999cited by this paper
• Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation

  1999cited by this paper
• BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair*

  1999cited by this paper
• Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions

  1999cited by this paper
• Replication error in human breast cancer: comparison with clinical variables and family history of cancer.

  1999cited by this paper
• BRCA1 physically associates with p53 and stimulates its transcriptional activity

  1998cited by this paper
• Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.

  1998cited by this paper
• Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.

  1998cited by this paper
• BRCA1 regulates p53-dependent gene expression.

  1998cited by this paper
• p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

  1998cited by this paper
• BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability.

  1998cited by this paper
• The genetics of breast cancer susceptibility.

  1998cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

  1997cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

  1997cited by this paper
• Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

  1996cited by this paper
• Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation

  1996cited by this paper
• Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage

  1996cited by this paper
• Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer.

  1996cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• Computer program for the analysis of mutational spectra: application to p53 mutations.

  1994influential reference
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper

• Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries

  2026cites this paper
• Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives

  2025cites this paper
• Characterization of tumor suppressors and oncogenes evaluated from TCGA cancers.

  2024cites this paper
• Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study

  2024cites this paper
• Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

  2024cites this paper
• Gynecologic and breast cancers with hereditary cancer predisposition syndromes

  2024cites this paper
• Targeting mutant p53: a key player in breast cancer pathogenesis and beyond

  2024cites this paper
• The role of p53 and ki67 in predicting clinical outcome in breast cancer patients

  2023cites this paper
• Association of ESR1 germline variants with TP53 somatic variants in breast tumors in a genome-wide study

  2023cites this paper
• Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations

  2023cites this paper
• BRCA1/2 haploinsufficiency: exploring the impact of losing one allele.

  2023cites this paper
• A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

  2023cites this paper
• Multi-scale characterisation of homologous recombination deficiency in breast cancer

  2023cites this paper
• The Apoptotic Resistance of BRCA1-Deficient Ovarian Cancer Cells is Mediated by cAMP

  2022cites this paper
• Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

  2022cites this paper
• Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer

  2022cites this paper
• Involvement of Xeroderma Pigmentosum Complementation Group G (XPG) in epigenetic regulation of T-Helper (TH) cell differentiation during breast cancer.

  2022cites this paper
• TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome

  2022cites this paper
• Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.

  2022cites this paper
• Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis

  2021cites this paper
• CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

  2021cites this paper
• Characterization of Alcohol-Mediated Promotion of Breast Cancer Stem Cells

  2021cites this paper
• OTT_A_321949 4967..4978

  2021cites this paper
• TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer

  2021cites this paper
• Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance

  2021cites this paper
• Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration

  2021cites this paper
• Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

  2020cites this paper
• Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes

  2020cites this paper
• The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.

  2020cites this paper
• Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

  2020cites this paper
• TP53, SPOP and PIK3CA Genes Status in Prostate Cancer

  2020cites this paper
• Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

  2020influential citation
• CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors

  2020cites this paper
• Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation

  2019cites this paper
• Correcting errors in the BRCA1 warning system.

  2019cites this paper
• Prevention of Breast Cancer by Food Bioactives in Relation to Cancer Subtypes

  2019cites this paper
• Targeting DNA repair in breast cancer.

  2019cites this paper
• Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures

  2019cites this paper
• Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2

  2019cites this paper
• Markers of BRCAness in breast cancer

  2019cites this paper
• Studies of Breast Cancer Chemoprevention in Human High-Risk Primary Cells and Genetically Engineered Mouse Models

  2018cites this paper
• REACTIVIVATION OF P53: TARGET TO TREAT BREAST CANCER

  2018cites this paper
• Molecular Oncology of Breast Cancer

  2018cites this paper
• BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression

  2018cites this paper
• BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage

  2018cites this paper
• Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment

  2018cites this paper
• Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant

  2017cites this paper
• The fate of BRCA1-related germline mutations in triple-negative breast tumors.

  2017cites this paper
• Homologous Recombination and Replication Fork Protection: BRCA2 and More!

  2017cites this paper
• Tissue-Based Biomarkers of Tumor-Vascular Interactions

  2017cites this paper
• Treatment of BRCA 1 / 2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• Breast Cancer Epigenetics: Modification by Genistein

  2017cites this paper
• “Biological significance of germline alterations in BRCA1 and BRCA2 genes and response to DNA damage agents in hereditary breast cancer”

  2017cites this paper
• Treatment of BRCA1/2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor.

  2017cites this paper
• The Dawning of Translational Breast Cancer: From Bench to Bedside.

  2017cites this paper
• Understanding the role of the PALB2-BRCA1 interaction in tumor suppression

  2017cites this paper
• Rad51 catalytic mutants differentially affect the Rad51 nucleoprotein filament in vivo

  2016cites this paper
• The identification of novel strategies for the prevention and treatment of breast cancer in BRCA1-mutation carriers

  2016cites this paper
• The Windows of Susceptibility to Breast Cancer

  2016cites this paper
• Next Generation Diagnostic Molecular Pathology

  2016cites this paper
• Germline Mutations in CHEK1 and CHEK2 in Women with Ovarian, Peritoneal, or Fallopian Tube Cancer

  2015cites this paper
• Identification of pathways involved in breast cancer susceptibility - contribution of SuprMam loci

  2015cites this paper
• Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression

  2015cites this paper
• Concurrent DNA Copy‐Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients

  2015cites this paper
• Hereditary Breast Cancer Syndromes: Molecular Pathogenesis and Diagnostics

  2015cites this paper
• BRCA2-associated therapy-related acute myeloid leukemia

  2015cites this paper
• Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer

  2015cites this paper
• ROLE OF BRCA1 AND BRCA2 GENES IN CELLULAR METABOLISM AND BREAST CANCER

  2015cites this paper
• The molecular and genetic basis of inherited cancer risk in gynaecology

  2015cites this paper
• GermlineMutations and Polymorphisms in the Origins of Cancers inWomen

  2014cites this paper
• Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics

  2014cites this paper
• brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish

  2014cites this paper
• SERIAL ESTIMATION OF CA 15.3 CAN PREDICT THE OUTCOME IN PATIENTS WITH BREAST CANCER – A PROSPECTIVE STUDY.

  2014cites this paper
• BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

  2014cites this paper
• Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations

  2014influential citation
• Systemic Treatment Considerations for Women with BRCA1/2-Associated Breast Cancer

  2014cites this paper
• Journal of Biotechnology Research Center (Special edition) Vol. 8 No. 1

  2014cites this paper
• We are all individuals… bioinformatics in the personalized medicine era

  2014cites this paper
• DEVELOPMENT OF A FUNCTIONAL ASSAY FOR DETERMINATION OF BRCA1 CARRIER STATUS

  2014cites this paper
• ATR inhibition preferentially targets homologous recombination-deficient tumor cells

  2014cites this paper
• Targeting Homologous Recombination Repair In Cancer Cells

  2014cites this paper
• Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

  2014cites this paper
• Novel Approaches to Studying BRCA Variants of Unknown Clinical Significance

  2014cites this paper
• Loss of expression of tumor suppressor gene SCARA5 in human breast cancer

  2014cites this paper
• Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.

  2013cites this paper
• First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report

  2013cites this paper
• Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.

  2013cites this paper
• Autophagy opposes p 53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB 2-associated hereditary breast cancer

  2013cites this paper
• PALB2 and RAP80 genes in hereditary breast cancer predisposition

  2013cites this paper
• Endogenous levels of Rad51 and Brca2 are required for homologous recombination and regulated by homeostatic re-balancing.

  2013cites this paper
• The etiology and prevention of breast cancer.

  2012cites this paper
• PARP1 expression in breast cancer and effects of its inhibition in preclinical models

  2012cites this paper
• BRCA1 – Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer

  2012cites this paper
• Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer

  2012cites this paper
• Evolution of the cancer genome

  2012cites this paper
• High levels of wild-type BRCA2 suppress homologous recombination.

  2012cites this paper
• The rebel angel: mutant p53 as the driving oncogene in breast cancer

  2012cites this paper
• Genetic factors in childhood cancer. Associations between tumors in childhood and adulthood, and prevalence of germline TP53 mutations

  2012cites this paper
• Pathology of hereditary breast cancer

  2011cites this paper